Related Experiment Video
Updated: Jun 3, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Venlafaxine withdrawal syndrome
Vladimir Sabljić1, Klementina Ružić, Radmir Rakun
1University Psychiatric Clinic, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia. Vladimir.sablic@ri.t-com.hr
Psychiatria Danubina
|March 31, 2011
Summary
Abruptly stopping serotonin-norepinephrine reuptake inhibitors (SRNIs) like venlafaxine can cause severe withdrawal symptoms. Prompt re-administration of venlafaxine effectively resolves these symptoms, highlighting the importance of patient education.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Serotonin-norepinephrine reuptake inhibitors (SRNIs) are crucial for depression treatment.
- Venlafaxine, an SRNI, is recognized for its efficacy and safety.
- Abrupt discontinuation of venlafaxine carries a significant risk of withdrawal syndrome, often more intense than with SSRIs.
Purpose of the Study:
- To present a case study of severe venlafaxine withdrawal syndrome.
- To illustrate the diagnostic challenges and effective treatment of this condition.
- To emphasize the importance of informing patients about potential withdrawal risks.
Main Methods:
- A case report of a 70-year-old patient experiencing severe symptoms after discontinuing venlafaxine.
- Neurological examination, CT scans, and laboratory tests were performed.
- Diagnosis was confirmed through psychiatric observation and response to treatment.
Main Results:
- The patient developed severe withdrawal symptoms mimicking a stroke shortly after discontinuing venlafaxine (225 mg/day).
- Neurological and laboratory assessments revealed no abnormalities.
- Readministration of venlafaxine (150 mg/day) led to rapid symptom resolution and full recovery.
Conclusions:
- Venlafaxine withdrawal syndrome is a significant risk that necessitates patient awareness.
- Early recognition and prompt treatment, often involving venlafaxine re-initiation, are key to managing withdrawal.
- Informing patients about potential discontinuation effects can mitigate risks and reduce healthcare costs.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...